publication . Review . Article . 2014

Update on ranolazine in the management of angina

Codolosa, J Nicolás; Acharjee, Subroto; Figueredo, Vincent M;
Open Access English
  • Published: 01 Jun 2014 Journal: Vascular Health and Risk Management, volume 10, pages 353-362 (issn: 1178-2048, eissn: 1178-2048, Copyright policy)
  • Publisher: Dove Press
Abstract
J Nicolás Codolosa,1 Subroto Acharjee,1 Vincent M Figueredo1,2 1Einstein Center for Heart and Vascular Health, Einstein Medical Center, 2Jefferson Medical College, Philadelphia, PA, USA Abstract: Mortality rates attributable to coronary heart disease have declined in recent years, possibly related to changes in clinical presentation patterns and use of proven secondary prevention strategies. Chronic stable angina (CSA) remains prevalent, and the goal of treatment is control of symptoms and reduction in cardiovascular events. Ranolazine is a selective inhibitor of the late sodium current in myocytes with anti-ischemic and metabolic properties. It was ...
Subjects
free text keywords: coronary artery disease, chronic stable angina, RC666-701, Review, Diseases of the circulatory (Cardiovascular) system, ranolazine, Vascular Health and Risk Management
61 references, page 1 of 5

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.

2. Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File 1999-2009. Underlying causeof-death 1999-2009. Available from: http://wonder.cdc.gov/mortSQl. html. Accessed February 25, 2014.

3. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155-2165.

4. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23): 2388-2398.

5. Silverman ME. William Heberden and some account of a disorder of the breast. Clin Cardiol. 1987;10(3):211-213.

6. National Institutes of Health. National Heart, Lung, and Blood Institute. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases; 2006. Available from: https://www.nhlbi.nih.gov/ resources/docs/06a_ip_chtbk.pdf. Accessed May 13, 2014.

7. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003.

8. US Food and Drug Administration. FDA approves new treatment for chest pain. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108587.htm. Accessed February 25, 2014.

9. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469-491.

10. Ranexa. Full prescribing information. Available from: http://www. gilead.com/∼/media/Files/pdfs/medicines/cardiovascular/ranexa/ ranexa_pi.ash. Accessed February 25, 2014.

11. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45(4):422-433.

12. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Ther. 2004;9 Suppl 1:S65-S83.

13. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8(8):1281-1290. [OpenAIRE]

14. Tavazzi L. Ranolazine, a new antianginal drug. Future Cardiol. 2005;1:1-9.

15. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33(2):243-257.

61 references, page 1 of 5
Abstract
J Nicolás Codolosa,1 Subroto Acharjee,1 Vincent M Figueredo1,2 1Einstein Center for Heart and Vascular Health, Einstein Medical Center, 2Jefferson Medical College, Philadelphia, PA, USA Abstract: Mortality rates attributable to coronary heart disease have declined in recent years, possibly related to changes in clinical presentation patterns and use of proven secondary prevention strategies. Chronic stable angina (CSA) remains prevalent, and the goal of treatment is control of symptoms and reduction in cardiovascular events. Ranolazine is a selective inhibitor of the late sodium current in myocytes with anti-ischemic and metabolic properties. It was ...
Subjects
free text keywords: coronary artery disease, chronic stable angina, RC666-701, Review, Diseases of the circulatory (Cardiovascular) system, ranolazine, Vascular Health and Risk Management
61 references, page 1 of 5

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.

2. Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File 1999-2009. Underlying causeof-death 1999-2009. Available from: http://wonder.cdc.gov/mortSQl. html. Accessed February 25, 2014.

3. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155-2165.

4. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23): 2388-2398.

5. Silverman ME. William Heberden and some account of a disorder of the breast. Clin Cardiol. 1987;10(3):211-213.

6. National Institutes of Health. National Heart, Lung, and Blood Institute. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases; 2006. Available from: https://www.nhlbi.nih.gov/ resources/docs/06a_ip_chtbk.pdf. Accessed May 13, 2014.

7. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003.

8. US Food and Drug Administration. FDA approves new treatment for chest pain. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108587.htm. Accessed February 25, 2014.

9. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469-491.

10. Ranexa. Full prescribing information. Available from: http://www. gilead.com/∼/media/Files/pdfs/medicines/cardiovascular/ranexa/ ranexa_pi.ash. Accessed February 25, 2014.

11. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45(4):422-433.

12. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Ther. 2004;9 Suppl 1:S65-S83.

13. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011;8(8):1281-1290. [OpenAIRE]

14. Tavazzi L. Ranolazine, a new antianginal drug. Future Cardiol. 2005;1:1-9.

15. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33(2):243-257.

61 references, page 1 of 5
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Review . Article . 2014

Update on ranolazine in the management of angina

Codolosa, J Nicolás; Acharjee, Subroto; Figueredo, Vincent M;